Previous Scholarships

The purpose of the project is to find out if the technology and methods function in human kidneys as well as validate the product prototype to pave the way for efficient and successful commercialization, i.e., the first part of the clinical study. Through this, the number of donor kidneys available for transplantation is expected to rise greatly and as quickly as possible.

We are developing objective and quantitative measurement tools that measure cerebellar function in combination with a modernized motor assessment test. We believe this can potentially revolutionize the way we assess and study ADHD and ASD – two diagnoses that cover several hundred thousand children in Sweden alone. In fact, our VR application may have an even wider applicability. For example, all four-year-olds in Sweden go through a motor assessment battery of tests that is used as an initial screening tool.

Classical tissue engineering strategies are patient-specific, thus clearly associated with inherent limits: a time-consuming graft production and a complex/costly production. Most importantly those cell-based strategy only allows for autologous use of the generated grafts. Here, we will validate the large-scale production and pre-clinical performance of a unique bone graft substitute. If successful, our cell-free cartilage product will bypass limits of existing tissue engineered strategies.

The aim of the project is to investigate the connection between diet/berries, microbiota and the effect on cognition and the pathological changes linked to Alzheimer’s disease. Above all, we hope to be able to find links to APOE4, which half of all Alzheimer’s patients have, and which is a cholesterol-carrying protein. We hope to find new mechanisms linked to APOE4, which could be exploited by dietary intervention.

Most surgical interventions (biopsy collections, microinjections, implant insertions, etc.) in the brain are performed with little regard to the mechanical forces that are generated in the various brain structures. Our findings suggest that unique surgical force-mitigation strategies represent a significant advance and a unique commercial opportunity. This work is of significance to both scientific and clinical communities working in biomaterials, neurotechnology, and brain disease research.

In Sweden alone, there are > 30,000 strokes/year, causing major impact on individuals and society (16 B SEK/year). During the 80 000 annual ultrasound examinations, most individuals with dangerous plaques are missed, as there is currently no method to assess plaque composition. Our method is needed for 1) clinical investigations, 2) screening high-risk individuals before they suffer from a heart attack or stroke and 3) evaluating novel treatments in the pharmaceutical industry fast and cheap.

Cancer treatment has never been better than it is today. This also implies that today more people than ever are living with a cured or surgically removed cancer. Unfortunately, this often means a lifelong risk of relapse. Individualized cancer vaccines could reduce that risk for many millions of people globally. For another group of patients, where existing treatment options are insufficient, cancer vaccines combined with existing immunotherapy can represent a completely new treatment option.

PeckiiLess will not only remove the invasiveness, waste and high cost of current methods, we will offer an accurate monitoring product for the roughly 40% of people who need to check their glucose but do not have access to the technology due to their limitations. The purpose of the application to the Sten K foundation is to obtain funds for PeckiiLess to further the research on the nanosensor with experts at Lund University. We have worked with Nano Lund in the past and seek to further this work

Most SCLC patients survive one year or less after diagnosis. Our aim is to develop a drug against SCLC, which is both more effective than the current treatment recommendations and which also leads to fewer side effects. The hypothesis that we want to evaluate is whether treatment with L12 shows a better effect than the therapies that are available today, as well as evaluate basic pharmacokinetic properties of the molecule.

Our solution is perfectly suited for the screening of the population above 50 years. As 40 percent of dementia are preventable by lifestyle changes, being able to screen the entire population could prevent ten million cases of Alzheimer’s. What is more, if an effective medication is put on the market (there are more than 20 phase 3 clinical trials for Alzheimer’s drugs currently), then patients could be treated in time, before their cognitive abilities decline.

The goal of the project is to in a smart, quick and safe way assess movement quality in different environments (e.g., by physiotherapists, occupational therapists, ergonomists, in sports and the workplace) by developing and evaluating a method where artificial intelligence assesses movement quality via a mobile application. The results from the mobile application can guide rehabilitation and preventive measures to improve movement quality, which can reduce the risk of injury / illness, improve performance and the work environment.

The aim of the project is to develop a new cancer treatment in the form of antibodies to SLAMF6 that can activate the body’s own T cells to attack cancer stem cells, primarily in acute myeloid leukaemia (AML) but potentially also in other cancers. The funds sought would enable the development of therapeutic antibodies by financing patent protection for SLAMF6 as a target for leukaemia stem cells and for the promising antibody to SLAMF6 that we have recently generated.

The aim is to eventually develop an antibody-based treatment that attacks the leukemic stem cells in AML. We have discovered a certain receptor shows specifically on the cell surface in one of the most common forms of AML. The receptor does not shown on normal blood stem cells and with the help of antibodies we can target treatment to the diseased cells without damaging the healthy blood cells. As part of the continued development of a new drug, our intention now is to protect our discovery by filing a patent application.

My goal with this project is to produce and commercialize cutting-edge laboratory equipment intended for more optimal cell cultures. Traditional cell cultivation has major limitations, and I see great potential in being able to satisfy the need for more functional cells. It is therefore my intention, through the development of new technical tools, as well as with solid results that demonstrate the potential of the equipment, to convey a positive change for research, healthcare, and society.

Our main objective is to fill the gap in the existing solutions that help patients in the rehabilitation process of male urinary incontinence. We want to deliver to patients a non-invasive pair of shorts that tracks their exercise and delivers real time evaluation of their performance.

The object of the project is to evaluate a completely new investigation algorithm based on endodrill biopsy under local anaesthesia instead of TURB under anaesthesia. The aim is to reduce the time until definitive treatment of MIBC is initiated, since such time delay diminishes the chances of curing this potentially serious tumour where today only every other patient is cured despite radical surgery. We also predict that the new algorithm implies less patient discomfort and is more economically beneficial than TURB.

The goal of this project is the formation of an innovation company whose focus is to produce and commercialize cutting-edge laboratory equipment intended for more optimal cell culture. Traditional cell culture has fundamental limitations, and I see great potential in being able to satisfy the need for more functional cells. It is therefore my intention to, through the development of new opportunities and tools, bring about a positive change for research, healthcare, and society.

Our overall purpose is to demonstrate that novel bacterial strains can prevent obesity and associated comorbidities. This pre-clinical proof-of-concept project aims at testing the efficacy of 4 anaerobic butyrate-producing bacterial strains in reducing gut inflammation, promoting metabolic health, and improving brain function. Promising strain will be further evaluated in clinical trials, and then developed into functional food products or supplements for a next-generation probiotics.

The geriatric patient after trauma is a very fragile patient category. Any kind of movement impacts greatly, and remedial general pain relief can give risky side effects. We intend to give staff earlier in the care chain a tool to be able to give the patient a topical pain relief, by being able to mark with artificial intelligence in ultrasound images where the block should be applied. This would increase the safety, well-being and security for this vulnerable group of patients.

Glymphatic system and its manipulations have been extensively characterized in rodent models. The overall goal of this study is to implement C-FLUSH therapy to enhance the brain-wide solute clearance in a higher mammal to enable its clinical therapeutic translation. Herein, we aim to optimize and characterize the efficacy of C-FLUSH on fluorescently tagged amyloid-beta or related agent introduced into the cleaning system (CSF) or brain parenchyma and assess it clearance to the periphery.